In line with this, a recent study shows that tumor cell-intrinsic PD-1 expression suppresses the canonical signaling pathways, including AKT and ERK1/2 in NSCLCs and colon cancer, while mTOR signaling remains unaffected.21 Treatment with either nivolumab (anti-PD-1 antibody) or ateolizumab (anti-PD-L1 antibody) enhances the growth of NCI-H1299 transplanted tumors in NOD-SCID IL-2 receptor gamma null mouse, one of the most immunodeficient mouse strains (figure 4). The gene discussed is CD274; the disease is colonic neoplasm.